Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation

Hepatocellular carcinoma (HCC) is disease with a high mortality rate and limited treatment options. Alterations of fibroblast growth factor receptor 4 (FGFR4) has been regarded as an oncogenic driver for HCC and a promising target for HCC therapeutics. Herein, we report that GNF-7, a multi-targeted...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yunju Nam, Injae Shin, Younghoon Kim, SeongShick Ryu, Namdoo Kim, Eunhye Ju, Taebo Sim
Formato: article
Lenguaje:EN
Publicado: Elsevier 2022
Materias:
HCC
SAR
Acceso en línea:https://doaj.org/article/e355c3f209df48bb95c0874512458e1d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!